Literature DB >> 23439432

Blockade of Smad signaling by 3'-deoxyadenosine: a mechanism for its anti-fibrotic potential.

Liubao Gu1, Hisashi Johno, Shotaro Nakajima, Hironori Kato, Shuhei Takahashi, Ryohei Katoh, Masanori Kitamura.   

Abstract

Cordyceps militaris has been used in Eastern countries for the treatment of various diseases including chronic kidney diseases. However, there are no reports that identified its active entities and molecular mechanisms underlying its therapeutic effectiveness. 3'-Deoxyadenosine is a major nucleoside derivative isolated from C. militaris. Some reports suggested that both C. militaris and 3'-deoxyadenosine have anti-inflammatory and anti-fibrotic effects. In the present report, we investigated whether and how 3'-deoxyadenosine interferes with fibrogenic processes in the kidney. For this purpose, we examined effects of 3'-deoxyadenosine on the expression of collagens triggered by transforming growth factor-β (TGF-β1) and bone morphogenetic protein-4 (BMP-4), especially focusing on the regulation of Smad signaling in vitro and in vivo. We found that 3'-deoxyadenosine suppressed expression of collagens induced by TGF-β1 and BMP-4 dose dependently. This suppression occurred at the transcriptional level and was correlated with blunted activation of the CAGA box and the BMP-responsive element. The suppressive effect on the TGF-β/BMP signaling was mediated mainly by adenosine transporter and partially by the A3 adenosine receptor, but not A1/A2 adenosine receptors. 3'-Deoxyadenosine reduced levels of both phosphorylated and total Smad proteins (Smad1, 2 and 3) dose dependently. It was mainly ascribed to transcriptional suppression, but not to enhanced protein degradation and eIF2α-mediated translational suppression. Consistent with the in vitro results, in vivo administration with 3'-deoxyadenosine reduced the levels of phosphorylated and total Smad proteins, as well as the levels of Smad mRNAs, in the kidney subjected to unilateral ureteral obstruction. It was associated with blunted induction of type I collagen and α-smooth muscle actin, a decrease in the number of interstitial myofibroblasts and reduced fibrotic area. These results suggest that 3'-deoxyadenosine interferes with the TGF-β and BMP signaling via downregulation of Smads, which may underlie the anti-fibrotic effect of this agent. 3'-Deoxyadenosine may be useful for therapeutic intervention in various TGF-β-related fibrotic disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23439432     DOI: 10.1038/labinvest.2013.4

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  5 in total

Review 1.  Mechanism of Cordyceps sinensis and its Extracts in the Treatment of Diabetic Kidney Disease: A Review.

Authors:  Wu Liu; Yiwei Gao; Yi Zhou; Fangning Yu; Xinyi Li; Ning Zhang
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

2.  Higher Anti-Liver Fibrosis Effect of Cordyceps militaris-Fermented Product Cultured with Deep Ocean Water via Inhibiting Proinflammatory Factors and Fibrosis-Related Factors Expressions.

Authors:  Yu-Ping Hung; Chun-Lin Lee
Journal:  Mar Drugs       Date:  2017-06-08       Impact factor: 5.118

3.  A Nucleoside/Nucleobase-Rich Extract from Cordyceps Sinensis Inhibits the Epithelial-Mesenchymal Transition and Protects against Renal Fibrosis in Diabetic Nephropathy.

Authors:  Zhonghua Dong; Yueyue Sun; Guangwei Wei; Siying Li; Zhongxi Zhao
Journal:  Molecules       Date:  2019-11-14       Impact factor: 4.411

Review 4.  A Systematic Review of the Biological Effects of Cordycepin.

Authors:  Masar Radhi; Sadaf Ashraf; Steven Lawrence; Asta Arendt Tranholm; Peter Arthur David Wellham; Abdul Hafeez; Ammar Sabah Khamis; Robert Thomas; Daniel McWilliams; Cornelia Huiberdina de Moor
Journal:  Molecules       Date:  2021-09-28       Impact factor: 4.411

Review 5.  Potential Therapeutic Strategies for Renal Fibrosis: Cordyceps and Related Products.

Authors:  Wei Tan; Yunyan Wang; Hongmei Dai; Junhui Deng; Zhifen Wu; Lirong Lin; Jurong Yang
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.